Difference in Restricted Mean Survival Time for Cost-Effectiveness Analysis Using Individual Patient Data Meta-Analysis: Evidence from a Case Study

Bias and precision of measures of survival gain from right-censored data

(2015) Karen E. Lamb et al.   PHARMACEUTICAL STATISTICS

Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data

(2015) Yinghui Wei et al.   STATISTICS IN MEDICINE

USING PREDICTION INTERVALS FROM RANDOM-EFFECTS META-ANALYSES IN AN ECONOMIC MODEL

(2014) Conor Teljeur et al.   INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE

Cost Effectiveness of Modified Fractionation Radiotherapy versus Conventional Radiotherapy for Unresected Non–Small-Cell Lung Cancer Patients

(2013) Bram L.T. Ramaekers et al.   Journal of Thoracic Oncology

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

(2013)   LANCET

Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data

(2013) Nicholas R. Latimer   MEDICAL DECISION MAKING

Individual Participant Data Meta-Analysis for a Binary Outcome: One-Stage or Two-Stage?

(2013) Thomas P. A. Debray et al.   PLoS One

Hyperfractionated or Accelerated Radiotherapy in Lung Cancer: An Individual Patient Data Meta-Analysis

(2012) Audrey Mauguen et al.   JOURNAL OF CLINICAL ONCOLOGY

Asymptotic properties of mean survival estimate based on the Kaplan-Meier curve with an extrapolated tail

(2012) Qi Gong et al.   PHARMACEUTICAL STATISTICS

Statistical Analysis of Individual Participant Data Meta-Analyses: A Comparison of Methods and Recommendations for Practice

(2012) Gavin B. Stewart et al.   PLoS One

Network meta-analysis of survival data with fractional polynomials

(2011) Jeroen P Jansen   BMC Medical Research Methodology

Surrogates, meta-analysis and cost-effectiveness modelling: a combined analytic approach

(2011) Neil Hawkins et al.   HEALTH ECONOMICS

Cautions Regarding the Fitting and Interpretation of Survival Curves

(2011) Martin Connock et al.   PHARMACOECONOMICS

The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt

(2011) Patrick Royston et al.   STATISTICS IN MEDICINE

Survival Time Outcomes in Randomized, Controlled Trials and Meta-Analyses: The Parallel Universes of Efficacy and Cost-Effectiveness

(2011) Patricia Guyot et al.   VALUE IN HEALTH

Survival Models in Health Economic Evaluations: Balancing Fit and Parsimony to Improve Prediction

(2010) Christopher H Jackson et al.  

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients

(2009) Jean-Pierre Pignon et al.   RADIOTHERAPY AND ONCOLOGY